Glasgow-based Solasta Bio, an agri-biotech company specializing in green insecticides, has raised €12.6 million in an oversubscribed Series A funding round. The round was led by Forbion’s BioEconomy fund, with co-leads FMC Ventures and Corteva Inc., and participation from existing investors such as Cavallo Ventures, Scottish Enterprise, and the University of Glasgow.
The funds will accelerate the development of Solasta Bio’s peptide-based bioinsecticides, designed to be safe for pollinators and offer a sustainable alternative to traditional chemicals.
Founded in 2021, Solasta Bio has developed a groundbreaking technology platform for creating insect control agents that selectively target harmful pests while protecting pollinators. These bioinsecticides match the effectiveness of current chemical products but are more environmentally friendly. Solasta Bio’s solution can be applied to a variety of pests in both crop and non-crop settings, including stored grain protection.
Advertisement
Global Expansion and Product Development
The new funding follows Solasta Bio’s successful 2023 trials, where its insect control agents outperformed commercial standards in field tests across Europe, the UK, and the US. The company will use the investment to expand its operations in the US, enhance biomanufacturing, and explore opportunities beyond agriculture. Solasta Bio aims to bring its first products to market by 2027, a faster timeline than typical synthetic pest control products.
Revolutionizing Crop Protection
CEO and co-founder Shireen Davies highlighted the company’s progress in developing its unique biopeptide technology, which has shown high efficacy in real-world trials. With a focus on solving grower challenges and promoting sustainable agriculture, the company is poised to become a leader in eco-friendly pest control.
